Other Information
−Removed: the quarter ended September 30, 2024, none of the Company’s directors or officers adopted , modified , or terminated a
−Removed: Rule 10b5-1 trading arrangement, or a non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408 of Regulation S-K.
−Removed: At-the-Market Sales Agreement, dated August 9, 2024, by and among INmune Bio Inc., RBC Capital Markets, LLC and BTIG, LLC (incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August 9, 2024)
−Removed: Form of Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on September 16, 2024)
−Removed: Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on September 16, 2024)
−Removed: Form of Placement Agency Agreement (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on September 16, 2024)
+Added: During the fiscal quarter
+Added: ended March 31, 2025, none of the Company’s directors or officers adopted , modified , or terminated a Rule 10b5-1 trading arrangement,
+Added: or a non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408 of Regulation S-K.
+Added: License Agreement, dated February 6, 2025, between INmune Bio Inc.
+Added: and Great Ormond Street Hospital for Children NHS Foundation Trust (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on February 10, 2025)
+Added: Termination Letter, dated February 6, 2025, between INmune Bio Inc.
+Added: and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on February 10, 2025)
Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer*
12 unchanged sentences
duly authorized.
−Removed: October 31, 2024
+Added: INmune Bio Inc.
Chief Executive Officer
(Principal Executive Officer)
−Removed: Financial Officer, Treasurer, Secretary
−Removed: Financial and Accounting Officer)
+Added: Chief Financial Officer, Treasurer, Secretary
+Added: (Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.